Real-world effects of lumacaftor/ivacaftor (LUM/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data

C. Kim (Boston, United States of America), C. Lee (Boston, United States of America), R. Zahigian (Boston, United States of America), N. Nair (Boston, United States of America), A. Sewall (Bethesda, United States of America), A. Elbert (Bethesda, United States of America)

Source: Virtual Congress 2021 – Clinical effects of CFTR modulatory therapy and lung inflammation in children with cystic fibrosis

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Kim (Boston, United States of America), C. Lee (Boston, United States of America), R. Zahigian (Boston, United States of America), N. Nair (Boston, United States of America), A. Sewall (Bethesda, United States of America), A. Elbert (Bethesda, United States of America). Real-world effects of lumacaftor/ivacaftor (LUM/IVA) in people with cystic fibrosis (pwCF): interim results of a long-term safety study using US CF Foundation Patient Registry (CFFPR) data. 2098

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Impact of the British Lung Foundation Active Steps service on patient reported outcomes:  concurrent cohort study
Source: Virtual Congress 2021 – A multidisciplinary approach to the management of chronic respiratory diseases
Year: 2021



Ten-year projected outcomes associated with increased use of triple therapies in UK patients with COPD using the COPD Health Outcome Policy and INtervention (CHOPIN) model
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021



Use of national disease registries in the conduct of long-term post-authorisation drug safety studies (LTSSs)
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016

From registry to quality management: the German Cystic Fibrosis Quality Assessment project 1995 2006
Source: Eur Respir J 2008; 31: 29-35
Year: 2008



Health resource utilisation due to IPF exacerbations in Spain: prospective, observational, multicentric study (OASIS study)
Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Year: 2020


Development of the Birmingham Lung Improvement Studies (BLISS) prognostic score for COPD patients in primary care: data from the Birmingham COPD cohort
Source: International Congress 2019 – Diagnosis and assessment of airway diseases in primary care
Year: 2019



The primary care routine data registry BeoNet: First pilot phase results for COPD research
Source: International Congress 2015 – Patient health gains related to the economic effectiveness of disease management programmes
Year: 2015

Disease characteristics and outcomes in a Swedish cohort of patients with pulmonary fibrosis (PF)
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Year: 2018


Health status predicts long-term outcomes in patients with chronic obstructive pulmonary disease (COPD): Pooled analysis of patient-level data from the COPD biomarker qualification consortium database
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015

CF-ABLE-UK score: Modification and validation of a clinical prediction rule for prognosis in cystic fibrosis on data from UK CF registry
Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous
Year: 2015


An Italian, observational, multicenter trial in female COPD patients: Preliminary data on the women reality in the MISTRAL study
Source: International Congress 2014 – Clinical assessment of airway diseases
Year: 2014


Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study
Source: Eur Respir J 2013; 41: 571-577
Year: 2013



Astro-Lab project: Assessment of the safety of long-acting beta agonists (LABAs) in asthma by combining health-care databases and direct patient follow-up: Description of the patient pattern in France and in the United-Kingdom (UK)
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013


Health economics of COPD: First results of the new German COSYCONET cohort compared to population-based controls from KORA
Source: International Congress 2014 – Highlights in respiratory epidemiology
Year: 2014

Gender differences in patients with severe asthma in real-life setting: data from the Severe Asthma Network in Italy (SANI) registry
Source: International Congress 2019 – Phenotypes and comorbidities of airway diseases
Year: 2019

The heterogeneity of bronchiectasis patient characteristics, management and outcomes across Europe: Data from the EMBARC registry
Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Year: 2018

Demographic, clinical and health care resource utilisation characterisation of patients prescribed omalizumab: A retrospective, real world data study
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014

Registries: roles, objectives and registry data study outcomes
Source: Eur Respir Monogr 2019; 85: 150-158
Year: 2019


Patient demographics and clinical characteristics in the UK Salford Lung Study (SLS COPD) and the European ACCESS study
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017


The effect of changes in quality of life in patients with lung cancer in the observation period (European Organization for Research and treatment of Cancer) EORTC QLQ-C 30 results of the evaluation and follow-up (AKAYAK-1 project)
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013